Parexel International Corp - Company Profile
Powered by 
All the data and insights you need on Parexel International Corp in one report.
$295
- Save hours of research time and resources with
our up-to-date Parexel International Corp Strategy Report
- Understand Parexel International Corp position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Parexel International Corp (Parexel), a subsidiary of Pamplona Capital Management LLP is a biopharmaceutical outsourcing service company. It provides services for managing the biopharmaceutical product lifecycle and for the development and commercialization of new medical therapies. It offers an array of services including clinical trials management, observational studies and patient/disease registries, data management, biostatistical analysis, epidemiology, health economics/outcomes research, pharmacovigilance, medical communications, clinical pharmacology, patient recruitment, clinical supply and drug logistics, post-marketing surveillance, regulatory and product development, and commercialization consulting among others. Parexel caters its products and services to pharmaceutical, biotechnology and medical device industries worldwide. The company offers its services through a network of offices in the Americas, Asia Pacific and EMEA countries across the world. Parexel is headquartered in Durham, North Carolina, the US.
Headquarters
United States of America
Address
2520 Meridian Parkway, Durham, North Carolina, 27713
Website
www.parexel.com
Telephone
1 919 5443170
Industry
Pharmaceuticals and Healthcare
Parexel International Corp premium industry data and analytics
Products and Services
| Services | Brands |
|---|---|
| Data Management | IMPACT CTMS |
| Clinical Pharmacology | TrialWorks |
| Related Medical Advisory | DataLabs EDC |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | New Products/Services | In February, the company announced the launch of new expert series - New Medicines, Novel Insights. |
| 2022 | Contracts/Agreements | In December, the company entered into a collaboration with MyEyeDr, to increase patient access and participation in ophthalmology clinical trials. |
| 2022 | Corporate Changes/Expansions | In September, the company opened clinical trial supplies and logistics depot in Suzhou, China. |
Competitor Comparison
| Key Parameters | Parexel International Corp | IQVIA Holdings Inc | Laboratory Corp of America Holdings | ICON Plc | Cellero LLC |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | Ireland | United States of America |
| City | Durham | Durham | Burlington | Dublin | Lowell |
| State/Province | North Carolina | North Carolina | North Carolina | Dublin | Massachusetts |
| No. of Employees | - | 87,000 | 67,000 | 41,100 | - |
| Entity Type | Private | Public | Public | Public | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Jamie Macdonald | Chief Executive Officer; Director | Executive Board | 2018 | - |
| Greg Rush | Chief Financial Officer | Senior Management | 2018 | - |
| Jonathan E. Shough | Chief Information Officer | Senior Management | 2022 | - |
| Michael Crowley | Chief Administrative Officer; Executive Vice President; General Counsel | Senior Management | 2020 | - |
| Amy McKee | Chief Medical Officer; Head - Oncology Center of Excellence | Senior Management | 2022 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer